Loading...

CLYM CLIMB BIO INC Legal Disputes 8-K Filing

CLMB

CLYM

CLIMB BIO INC

(CLYM)

2025 8-K

Management Change

Financial Results Announced

Pipeline Progress Update

Litigation Update

Stock Exchange Agreement

Financial Results Report

Clinical Data Update

CFO Appointment

Investor Event Update

Financial Statements

Equity Agreement

Licensing Agreement

Financial Results

Financial Update

Management Changes

Management Change

Financial Results

Acquisition and Private Pla...

Annual Meeting Results

Appointment of President, C...

Acquisition Agreement

Exploring Potential Transac...

Management Changes

Annual Meeting of Stockholders

Financial Results Announcement

Management Changes

Financial Results Announcement

Restructuring and Leadershi...

Resignation of Director

External Links:

Climb Bio, Inc. filed a complaint on December 31, 2025, against Alumis Inc. and Acelyrin, asserting that its budoprutug drug candidate is not a 'Product' under a previous Asset Purchase Agreement, thus it does not owe a demanded milestone payment.

AI Assistant

CLIMB BIO INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.